Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
- None.
- None.
The availability of Nu.Q® Vet Cancer Test in veterinary clinics marks a significant stride in the early detection and management of cancer in dogs. By providing rapid and accurate diagnostic capabilities at the patient's side, this test leverages the latest in epigenetic technology, addressing a growing demand for advanced veterinary care. In terms of market implications, this product introduction may lead to an increased revenue stream for VolitionRx from sales to vet clinics, bolstered by the partnership with Antech, a reputable player in the veterinary space.
From a financial perspective, the adoption rate of the Nu.Q® Vet Cancer Test could serve as a key indicator of future performance for VolitionRx. Investors should monitor the company’s quarterly earnings reports for mentions of sales volume and revenue attributed to this product. Additionally, given the test's appeal to high-risk breeds and older dogs, the target market is well-defined, which may lead to effective marketing strategies and partnerships, further driving adoption.
Volition's strategic move to partner with Antech could be an indicator of an aggressive market penetration strategy for the Nu.Q® Test, leveraging Antech's existing in-clinic infrastructure. This partnership might reduce barriers to entry for Volition's product in a competitive field and create a symbiotic relationship where Antech benefits from an expanded product offering. For investors, partnerships like this can be a sign of a company's commitment to scalability and market reach.
Investor attention should also be on competitive responses and the broader market reaction to this innovation. While the introduction of in-clinic testing is transformative, it's important to assess whether competitors will launch similar tests, which could dilute market share or lead to price competition. Monitoring patent filings and regulatory announcements can provide foresight into these potential developments.
Antech's in-clinic version of the Nu.Q® Canine Cancer Test operates on the Element i+® Analyzer, providing veterinarians with a rapid, accurate and cost-effective cancer screening tool for high-risk breeds and older dogs, at the patient side, with results in about six minutes.
Dr Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: "Through this collaboration, our groundbreaking Nu.Q® technology is now available to veterinarians across the
Dr Butera added:
"Antech's rollout of the Nu.Q® Canine Cancer Test marks a huge step forward for Volition as we seek to fulfil our mission of ensuring our epigenetic technology is accessible and affordable worldwide, to detect and monitor disease earlier and improve outcomes."
Volition's original license and supply agreement was between Belgian Volition SRL and Heska, an Antech company, part of Mars Science & Diagnostics.
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis. For more information about Volition's technology go to: www.volition.com
Notes:
[1] Wilson-Robles, H.M., Bygott, T., Kelly, T.K. et al. Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Vet Res 18, 329 (2022). https://doi.org/10.1186/s12917-022-03429-8
- According to The Veterinary Cancer Society, one in four dogs will be diagnosed with cancer, and it's the leading cause of death in pets who are beyond middle age.
- Approximately 190 million dogs in the U.S. (source) and
Europe (source)
About Volition
Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's and Antech's website addresses are not incorporated by reference into this document and should not be considered part of this document. Such website addresses are included in this document as inactive textual references only.
About Mars Science & Diagnostics and Antech
Mars Science & Diagnostics is a division of Mars Petcare, a diverse business dedicated to one purpose: A BETTER WORLD FOR PETS™. Science & Diagnostics brings together the power of leading pet health science with expertise across diagnostics, data, and technology to improve outcomes in pet health. Our veterinary diagnostics business Antech spans in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; 90+ reference laboratories around the globe; veterinary imaging and technology; education; and board-certified specialist support services. Our at-home diagnostics offering includes Wisdom Panel™ DNA test products, the world's most accurate pet DNA test. For 60 years, our Waltham Petcare Science Institute has been advancing science to better understand pet health.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 (0)7557 774620
Geraldine Varoqui, Antech, geraldine.varoqui@effem.com
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's estimated market opportunity, the effectiveness of Volition's blood-based diagnostic, prognostic and disease monitoring tests, and Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
Photo - https://mma.prnewswire.com/media/2394696/Antech_US_Europe_Element_i.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuq-vet-cancer-test-launched-in-clinic-in-us-and-europe-through-antech-302124578.html
SOURCE VolitionRx Limited
FAQ
What is the latest product launched by VolitionRx in the U.S. and Europe through Antech?
Which company is providing the in-clinic version of the Nu.Q® Canine Cancer Test?
What tool is used by veterinarians for the Nu.Q® Canine Cancer Test in clinics?
Who is the target audience for the Nu.Q® Vet Cancer Test?
